Azita Hajhossein Talasaz, Parham Sadeghipour, Hooman Bakhshandeh, Babak Sharif-Kashani, Farid Rashidi, Mohammad Taghi Beigmohammadi, Keivan Gohari Moghadam, Somayeh Rezaian, Ali Dabbagh, Seyed Hashem Sezavar, Mohsen Farrokhpour, Atefeh Abedini, Rasoul Aliannejad, Taghi Riahi, Mahdi Yadollahzadeh, Somayeh Lookzadeh, Parisa Rezaeifar, Samira Matin, Ooria Tahamtan, Keyhan Mohammadi, Elnaz Zoghi, Hamid Rahmani, Seyed Hossein Hosseini, Seyed Masoud Mousavian, Homa Abri, Pardis Sadeghipour, Elahe Baghizadeh, Farnaz Rafiee, Sepehr Jamalkhani, Ahmad Amin, Bahram Mohebbi, Seyed Ehsan Parhizgar, Mahshid Soleimanzadeh, Maryam Aghakouchakzadeh, Vahid Eslami, Pooya Payandemehr, Hossein Khalili, Hamed Talakoob, Taranom Tojari, Shadi Shafaghi, Sanaz Tabrizi, Hessam Kakavand, Alireza Kashefizadeh, Atabak Najafi, David Jiménez, Aakriti Gupta, Mahesh V Madhavan, Sanjum Sethi, Sahil A Parikh, Manuel Monreal, Naser Hadavand, Alireza Hajighasemi, Khalil Ansarin, Majid Maleki, Saeed Sadeghian, Stefano Barco, Bob Siegerink, Erica Spatz, Gregory Piazza, Ajay J Kirtane, Benjamin W Van Tassell, Gregory Yh Lip, Erik Klok, Samuel Z Goldhaber, Gregg Stone, Harlan Krumholz, Behnood Bikdeli
BACKGROUNDS: In the INSPIRATION-S trial, atorvastatin versus placebo was associated with a non-significant 16% reduction in 30-day composite of venous/arterial thrombosis or death in ICU patients with COVID-19. Thrombo-inflammatory response in COVID-19 may last beyond the first 30 days. METHODS: This article reports the effects of atorvastatin 20 mg daily versus placebo on 90-day clinical and functional outcomes from INSPIRATION-S, a double-blind multicenter randomized trial of adult ICU patients with COVID-19...
March 21, 2023: Thrombosis and Haemostasis